Key result
Oral administration of 4.5 g of L-2-oxo-4-thiazolidine carboxylate significantly improved brachial artery flow-mediated dilation to 11.0% compared to 7.2% with placebo in patients with coronary artery disease.
Why the study?
Does oral L-2-oxo-4-thiazolidine carboxylate improve endothelium-dependent flow-mediated dilation in patients with coronary artery disease?
RCT (n=48)
Double-blind
Randomized
No
Does oral L-2-oxo-4-thiazolidine carboxylate improve endothelium-dependent flow-mediated dilation in patients with coronary artery disease?
Absolute Event Rate: 11% vs 7.2%
p-value: p=0.005
Augmenting cellular glutathione levels with oral L-2-oxo-4-thiazolidine carboxylate significantly improves endothelium-dependent flow-mediated dilation in patients with coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Supports glutathione augmentation to improve endothelial function in CAD; extends ascorbic acid redox findings to a dedicated precursor.
Vita et al. (1998) conducted an RCT in Coronary artery disease (n=48). L-2-oxo-4-thiazolidine carboxylate (OTC) vs. Placebo was evaluated on Brachial artery flow-mediated dilation at 4 hours (p=0.005). Oral administration of 4.5 g of L-2-oxo-4-thiazolidine carboxylate significantly improved brachial artery flow-mediated dilation to 11.0% compared to 7.2% with placebo in patients with coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: